BIOSENSORS REPORTS STRONG SALES AND PROFITABILITY IN THE SECOND QUARTER AND FIRST HALF OF FISCAL YEAR 2013

Q2 FY13 and Recent Highlights:
Total revenue of US$79.8 million, representing 28% year-on-year growth

Interventional Cardiology Products (IVP) sales, largely comprising drug-eluting stent (DES) sales, increased substantially by 61% year-on-year to US$61.9 million
Gross margin on total product sales was 80%, a significant improvement of 9% year-on-year

Operating profit reached US$33.9 million, a 71% year-on-year increase, while net profit excluding exceptional items grew 36% year-on-year to US$29.2 million

A study published in August in the Journal of the American Medical Association (JAMA) confirms BioMatrix™reduces cardiac events in acute myocardial infarction (AMI) patients more effectively than a bare-metal stent

In October, Biosensors extended its licensing agreement with Terumo for territories outside the United States and Japan and positions itself for more strategic cooperation with Terumo in all sales territories, including Japan

At the Transcatheter Cardiovascular Therapeutics (TCT) conference in October, the Company released the final 5-year results for its ground-breaking LEADERS trial, demonstrating improved long-term clinical outcomes for BioMatrix Flex as compared to Cypher® Select™



See? Presentation slides